---
layout: default
title: Alfuzosin Hydrochloride
parent: 僅模型預測 (L5)
nav_order: 42
evidence_level: L5
indication_count: 0
---

# Alfuzosin Hydrochloride
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Alfuzosin Hydrochloride: Evaluation Report — Repurposing Prediction Unavailable

## One-Sentence Summary

Alfuzosin Hydrochloride is a selective alpha-1 adrenergic receptor antagonist primarily used to treat benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS).
The TxGNN model did not generate any repurposing predictions for this drug in the current run, likely due to upstream data gaps in the DrugBank mapping or KG node resolution.
A full repurposing evaluation cannot be conducted until key data gaps — package insert warnings, MOA, and complete license records — are resolved.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Benign Prostatic Hyperplasia (BPH) / Lower Urinary Tract Symptoms |
| Predicted New Indication | Not available |
| TxGNN Prediction Score | Not available |
| Evidence Level | N/A — No prediction generated |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | **Hold** |

---

## Background on Drug Mechanism

Currently, detailed mechanism of action data is not available from the evidence pack. Based on publicly available pharmacological information, Alfuzosin Hydrochloride belongs to the quinazoline class of alpha-1 adrenergic receptor antagonists. It selectively blocks alpha-1 receptors in the smooth muscle of the prostate, bladder neck, and urethra, thereby reducing urinary outflow resistance and alleviating obstructive symptoms associated with BPH.

As a class, alpha-1 blockers share a well-characterized mechanism that has been explored beyond BPH. Conditions such as ureteral colic (facilitating stone passage), hypertension, and certain voiding dysfunctions have been investigated with drugs in this class. However, without a confirmed TxGNN prediction score and associated disease node, it is not possible to identify or evaluate a specific repurposing candidate at this time.

The absence of a DrugBank ID in this evidence pack (drugbank_id: null) strongly suggests that the drug-node mapping step failed, which would explain why the TxGNN model produced no output. Resolving the DrugBank mapping is the most critical remediation step before re-running the prediction pipeline.

---

## Malaysia Market Information

> **Note:** The NPRA query returned **3 registered licenses** for Alfuzosin Hydrochloride (query date: 2026-03-27, status: success). However, the structured license record fields — product name, dosage form, manufacturer, and approved indication text — were not populated in this evidence pack. Please query the [NPRA Product Registration portal](https://www.npra.gov.my/) directly to retrieve the full registration details for these three products.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Data Gap DG001 (Blocking):** NPRA/TFDA package insert warnings and contraindications have not been retrieved. This prevents completion of the S1 safety screening. Remediation: download and parse the package insert PDF from the NPRA official website.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN model produced no repurposing predictions for this drug, and two critical data gaps — missing MOA and missing package insert safety data — prevent a meaningful repurposing evaluation. The root cause is most likely a failed DrugBank node mapping (drugbank_id is null), which must be resolved before re-running the prediction pipeline.

**To proceed, the following is needed:**

- **[DG002 — High Priority]** Query the DrugBank API to resolve the DrugBank ID for Alfuzosin Hydrochloride and obtain the mechanism of action. This is the most likely root cause of the missing TxGNN predictions.
- **[DG001 — Blocking]** Download and parse the NPRA package insert PDF to extract key warnings and contraindications, enabling the S1 safety screening step.
- **Complete license record retrieval:** Re-query the NPRA database to populate product names, dosage forms, manufacturers, and approved indication texts for all 3 registered licenses.
- **Re-run the TxGNN prediction pipeline** after the DrugBank mapping is resolved to generate repurposing candidates with prediction scores and associated disease nodes.
- **Re-generate this report** once the above gaps are remediated; the full template (clinical trial evidence, literature evidence, cytotoxicity assessment) will be populated accordingly.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

